American journal of ophthalmology case reports · 2026
Conjunctival stromal tumor: Longitudinal evolution of a progressive, infiltrating tumor.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Silhadi Meziane, Noorah Bibi Nuzha, Roberge David, Odashiro Alexandre N, Massicotte Erika, Robert Marie-Claude
Аннотация
PURPOSE: To report a case of progressive conjunctival stromal tumor (COST) resistant to surgical debulking and radiotherapy (RT), resulting in orbital exenteration.
OBSERVATIONS: A 43-year-old male presented with a hypervascularized nasal bulbar conjunctival lesion infiltrating the rectus muscles of the left eye. Despite three surgical debulking procedures, the tumor recurred and progressed, affecting the superior, nasal, and inferior bulbar conjunctiva and the lower eyelid. RT was administered (30 Gy in 10 fractions) with minimal tumor response. The tumor continued to expand, requiring orbital exenteration to prevent intracranial extension. Histopathology confirmed COST, and genomic testing revealed no actionable variants. The patient's postoperative course has been stable with no evidence of recurrence in the last 32 months.
CONCLUSIONS: This case highlights the limitations of RT in managing progressive COST. It underscores the importance of considering more aggressive surgical management in progressive cases. Further studies are needed to establish optimal treatment strategies for COST.
OBSERVATIONS: A 43-year-old male presented with a hypervascularized nasal bulbar conjunctival lesion infiltrating the rectus muscles of the left eye. Despite three surgical debulking procedures, the tumor recurred and progressed, affecting the superior, nasal, and inferior bulbar conjunctiva and the lower eyelid. RT was administered (30 Gy in 10 fractions) with minimal tumor response. The tumor continued to expand, requiring orbital exenteration to prevent intracranial extension. Histopathology confirmed COST, and genomic testing revealed no actionable variants. The patient's postoperative course has been stable with no evidence of recurrence in the last 32 months.
CONCLUSIONS: This case highlights the limitations of RT in managing progressive COST. It underscores the importance of considering more aggressive surgical management in progressive cases. Further studies are needed to establish optimal treatment strategies for COST.